Innovations in thoracic imaging: CT, radiomics, AI and x-ray velocimetry
- PMID: 35965430
- PMCID: PMC9546393
- DOI: 10.1111/resp.14344
Innovations in thoracic imaging: CT, radiomics, AI and x-ray velocimetry
Abstract
In recent years, pulmonary imaging has seen enormous progress, with the introduction, validation and implementation of new hardware and software. There is a general trend from mere visual evaluation of radiological images to quantification of abnormalities and biomarkers, and assessment of 'non visual' markers that contribute to establishing diagnosis or prognosis. Important catalysts to these developments in thoracic imaging include new indications (like computed tomography [CT] lung cancer screening) and the COVID-19 pandemic. This review focuses on developments in CT, radiomics, artificial intelligence (AI) and x-ray velocimetry for imaging of the lungs. Recent developments in CT include the potential for ultra-low-dose CT imaging for lung nodules, and the advent of a new generation of CT systems based on photon-counting detector technology. Radiomics has demonstrated potential towards predictive and prognostic tasks particularly in lung cancer, previously not achievable by visual inspection by radiologists, exploiting high dimensional patterns (mostly texture related) on medical imaging data. Deep learning technology has revolutionized the field of AI and as a result, performance of AI algorithms is approaching human performance for an increasing number of specific tasks. X-ray velocimetry integrates x-ray (fluoroscopic) imaging with unique image processing to produce quantitative four dimensional measurement of lung tissue motion, and accurate calculations of lung ventilation.
Keywords: computed tomography; deep learning; lung cancer; lung nodules; machine learning; radiomics; x-ray velocimetry.
© 2022 The Authors. Respirology published by John Wiley & Sons Australia, Ltd on behalf of Asian Pacific Society of Respirology.
Conflict of interest statement
Rozemarijn Vliegenthart is supported by an institutional research grant from Siemens Healthineers. Colin Jacobs is supported by an institutional research grant from MeVis Medical Solutions and his institution receives royalties from MeVis Medical Solutions for the development of Veolity, a reading platform for lung cancer screening. Nikolaos Papanikolaou is the owner of MRIcons LTD. Andreas Fouras is a founder and CEO of 4DMedical, a global medical technology company.
Figures
References
-
- Kauczor H‐U, Baird A‐M, Blum TG, Bonomo L, Bostantzoglou C, Burghuber O, et al. ESR/ERS statement paper on lung cancer screening. Eur Radiol. 2020;30:3277–94. - PubMed
-
- US Preventive Services Task Force , Krist AH, Davidson KW, Mangione CM, Barry MJ, Cabana M, et al. Screening for lung cancer: US preventive services task force recommendation statement. JAMA. 2021;325:962–70. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
